Could BioSig Technologies, Inc. (BSGM) See a Reversal After Breaking Its 52-Week High?

BioSig Technologies, Inc. (NASDAQ:BSGM) Logo

The stock of BioSig Technologies, Inc. (NASDAQ:BSGM) hit a new 52-week high and has $9.57 target or 8.00 % above today’s $8.86 share price. The 5 months bullish chart indicates low risk for the $180.81M company. The 1-year high was reported on May, 13 by If the $9.57 price target is reached, the company will be worth $14.46M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.62% or $0.06 during the last trading session, reaching $8.86. About 65,095 shares traded. BioSig Technologies, Inc. (NASDAQ:BSGM) has risen 61.18% since May 13, 2018 and is uptrending. It has outperformed by 56.81% the S&P500.

More notable recent BioSig Technologies, Inc. (NASDAQ:BSGM) news were published by: which released: “Johnson & Johnson’s Biosense Webster’s MaryAnn Edzards Joins BioSig – GlobeNewswire” on December 19, 2018, also with their article: “More Than 36,000 Pounds of Tyson Chicken Nuggets Recalled Over Possible Rubber Contamination – TIME” published on January 30, 2019, published: “BioSig To Participate at Heart Rhythm Society’s Scientific Sessions 2019 – GlobeNewswire” on April 30, 2019. More interesting news about BioSig Technologies, Inc. (NASDAQ:BSGM) were released by: and their article: “Virginia Sets Up First Historical Marker for Lynching Victim – TIME” published on April 09, 2019 as well as‘s news article titled: “Use of the Death Penalty Dropped to Lowest in a Decade, New Report Says – TIME” with publication date: April 10, 2019.

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company has market cap of $180.81 million. The Company’s product is PURE EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It currently has negative earnings. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.